Involvement of YKL-40-positive macrophages commonly identified in polymyositis and dermatomyositis in the pathogenesis of myositis: a retrospective study

References

• Johansen JS, Williamson MK, Rice JS, et al. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res. 1992;7(5):501–512. doi: 10.1002/jbmr.5650070506.
   PubMed Web of Science ®Google Scholar
• Shuhui L, Mok YK, Wong WS. Role of mammalian chitinases in asthma. Int Arch Allergy Immunol. 2009;149(4):369–377. doi: 10.1159/000205583.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Lee CG, Jarjour N, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007;357(20):2016–2027. doi: 10.1056/NEJMoa073600.
   PubMed Web of Science ®Google Scholar
• Tang H, Fang Z, Sun Y, et al. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J. 2010;35(4):757–760. doi: 10.1183/09031936.00034409.
   PubMed Web of Science ®Google Scholar
• Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172–209.
   PubMed Web of Science ®Google Scholar
• Schultz NA, Johansen JS. YKL-40—a protein in the field of translational medicine: a role as a biomarker in cancer patients? Cancers. 2010;2(3):1453–1491. doi: 10.3390/cancers2031453.
   PubMedGoogle Scholar
• Shao R, Francescone R, Ngernyuang N, et al. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis. 2014;35(2):373–382. doi: 10.1093/carcin/bgt380.
   PubMed Web of Science ®Google Scholar
• Shao R, Taylor SL, Oh DS, et al. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget. 2015;6(38):40507–40518. doi: 10.18632/oncotarget.5943.
   PubMedGoogle Scholar
• De Ceuninck F, Gaufillier S, Bonnaud A, et al. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285(4):926–931. doi: 10.1006/bbrc.2001.5253.
   PubMed Web of Science ®Google Scholar
• Turkyilmaz AK, Devrimsel G, Kirbas A, et al. Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis. Rheumatol Int. 2013;33(11):2751–2756. doi: 10.1007/s00296-013-2810-4.
   PubMed Web of Science ®Google Scholar
• Vind I, Johansen JS, Price PA, et al. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003;38:599–605.
   PubMed Web of Science ®Google Scholar
• Imai Y, Aochi S, Iwatsuki K, et al. YKL-40 (chitinase 3-like 1) as a biomarker for psoriasis vulgaris and pustular psoriasis. J Dermatol Sci. 2011;64(1):75–77. doi: 10.1016/j.jdermsci.2011.06.012.
   PubMed Web of Science ®Google Scholar
• Imai Y, Aochi S, Iwatsuki K, et al. YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis. J Dermatol. 2013;40(4):294–296. doi: 10.1111/1346-8138.12061.
   PubMed Web of Science ®Google Scholar
• Johansen JS, Christoffersen P, Møller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 2000;32(6):911–920. doi: 10.1016/s0168-8278(00)80095-1.
   PubMed Web of Science ®Google Scholar
• Chen G, Yang T, Gu Q, et al. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. Respirology. 2014;19(4):608–615. doi: 10.1111/resp.12283.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Matsui K, Kitano M, et al. Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis. Mod Rheumatol. 2019;29(3):476–483. doi: 10.1080/14397595.2018.1480256.
   PubMed Web of Science ®Google Scholar
• Melah KE, Lu SY, Hoscheidt SM, et al. Cerebrospinal fluid markers of Alzheimer’s disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer’s disease. J Alzheimers Dis. 2016;50(3):873–886. doi: 10.3233/JAD-150897.
   PubMed Web of Science ®Google Scholar
• Yeo IJ, Lee CK, Han SB, et al. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther. 2019;203:107394. doi: 10.1016/j.pharmthera.2019.107394.
   PubMed Web of Science ®Google Scholar
• Deutschmann C, Sowa M, Murugaiyan J, et al. Identification of chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn’s disease. J Crohns Colitis. 2019;13(7):894–904. doi: 10.1093/ecco-jcc/jjz012.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–407. doi: 10.1056/NEJM197502202920807.
   PubMed Web of Science ®Google Scholar
• Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51(5):638–656. doi: 10.1002/mus.24566.
   PubMed Web of Science ®Google Scholar
• Dalakas M. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325(21):1487–1498. doi: 10.1056/NEJM199111213252107.
   PubMed Web of Science ®Google Scholar
• Dalakas M, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–982. doi: 10.1016/S0140-6736(03)14368-1.
   PubMed Web of Science ®Google Scholar
• Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100(1):124S–127S. doi: 10.1111/1523-1747.ep12356896.
   PubMed Web of Science ®Google Scholar
• Kissel J, Mendell J, Rammohan K. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314(6):329–334. doi: 10.1056/NEJM198602063140601.
   PubMed Web of Science ®Google Scholar
• Emslie-Smith A, Engel A. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990;27(4):343–356. doi: 10.1002/ana.410270402.
   PubMed Web of Science ®Google Scholar
• Arahata K, Engel A. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193–208. doi: 10.1002/ana.410160206.
   PubMed Web of Science ®Google Scholar
• Nagaraju K, Lundberg IE. Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin North Am. 2011;37(2):159–171, v. doi: 10.1016/j.rdc.2011.01.002.
   PubMed Web of Science ®Google Scholar
• Venalis P, Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology. 2014;53(3):397–405. doi: 10.1093/rheumatology/ket279.
   PubMed Web of Science ®Google Scholar
• Hozumi H, Fujisawa T, Enomoto N, et al. Clinical utility of YKL-40 in polymyositis/dermatomyositis-associated interstitial lung disease. J Rheumatol. 2017;44(9):1394–1401. doi: 10.3899/jrheum.170373.
   PubMed Web of Science ®Google Scholar
• Jiang L, Wang Y, Peng Q, et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol. 2019;38(6):1655–1663. doi: 10.1007/s10067-019-04457-w.
   PubMed Web of Science ®Google Scholar
• Gao MZ, Wei YY, Xu QW, et al. Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis. Ann Clin Biochem. 2019;56(1):95–99. doi: 10.1177/0004563218786979.
   PubMed Web of Science ®Google Scholar
• Zhang PL, Yang HX, Zhang LN, et al. Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury. Beijing Da Xue Xue Bao Yi Xue Ban. 2021;53:1055–1060.
   PubMedGoogle Scholar
• Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta. 2011;412(9–10):709–712. doi: 10.1016/j.cca.2011.01.022.
   PubMed Web of Science ®Google Scholar
• Jensen KY, Jacobsen M, Schrøder HD, et al. The immune system in sporadic inclusion body myositis patients is not compromised by blood-flow restricted exercise training. Arthritis Res Ther. 2019;21(1):293. doi: 10.1186/s13075-019-2036-2.
   PubMed Web of Science ®Google Scholar
• Carboni RCS, Behrens Pinto GL, Shinjo SK. High YKL-40 serum levels and its expression in the muscle tissues of patients with antisynthetase syndrome. Adv Rheumatol. 2021;61(1):44. doi: 10.1186/s42358-021-00199-z.
   PubMedGoogle Scholar
• Rostasy KM, Piepkorn M, Goebel HH, et al. Monocyte/macrophage differentiation in dermatomyositis and polymyositis. Muscle Nerve. 2004;30(2):225–230. doi: 10.1002/mus.20088.
   PubMed Web of Science ®Google Scholar
• Peng QL, Zhang YL, Shu XM, et al. Elevated serum levels of soluble CD163 in polymyositis and dermatomyositis: associated with macrophage infiltration in muscle tissue. J Rheumatol. 2015;42(6):979–987. doi: 10.3899/jrheum.141307.
   PubMed Web of Science ®Google Scholar
• Horiike Y, Suzuki Y, Fujisawa T, et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology. 2019;58(12):2143–2152. doi: 10.1093/rheumatology/kez185.
   PubMed Web of Science ®Google Scholar
• Zuo Y, Ye L, Liu M, et al. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology. 2020;59(10):2829–2837. doi: 10.1093/rheumatology/keaa034.
   PubMed Web of Science ®Google Scholar
• Yin R, Wang G, Zhang L, et al. Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs. Clin Rheumatol. 2021;40(6):2301–2310. doi: 10.1007/s10067-020-05568-5.
   PubMed Web of Science ®Google Scholar
• Chen S, Li H, Zhan H, et al. Identification of hub biomarkers and immune cell infiltration in polymyositis and dermatomyositis. Aging. 2022;14(10):4530–4555. doi: 10.18632/aging.204098.
   PubMedGoogle Scholar